Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia.

Decker, T., Mündlein, A., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Hegewisch-Becker, S., Lerchenmüller, C., 2018.

Ann Oncol 29(suppl_8), 295P. doi:https://doi.org/10.1093/annonc/mdy272.285

Abstract